Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0193 • ACR Convergence 2020
Patients with Asthma Have a Higher Risk of Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Nipith Charoenngam¹, Ben Ponvilawan¹, Thanitsara Rittiphairoj¹, Surapa Tornsatitkul¹, Phuuwadith Wattanachayakul¹, Pongprueth Rujirachun¹ and Patompong Ungprasert², ¹Mahidol University, Bangkok, Thailand, ²Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH
Background/Purpose: Studies have reported the association between asthma and elevated risk of several chronic diseases, such as inflammatory bowel disease, diabetes mellitus and coronary heart…
Abstract Number: 0209 • ACR Convergence 2020
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks
Josef Smolen¹, Paul Emery², William Rigby³, Yoshiya Tanaka⁴, Juan Vargas⁵, Nemanja Damjanov⁶, Manish Jain⁷, Yanna Song⁸, Nasser Khan⁹, Jeffrey Enejosa⁹ and Stanley Cohen¹⁰, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ³Dartmouth College, Norwichi, VT, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Quantum Research, Puerto Varas, Chile, ⁶University of Belgrade Medical School, Belgrade, Serbia, ⁷Great Lakes Clinical Trials, Chicago, IL, ⁸AbbVie Inc., North Chicago,, IL, ⁹AbbVie Inc., North Chicago, IL, ¹⁰Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK inhibitor, demonstrated significantly greater efficacy compared to continuing methotrexate (MTX) when used as monotherapy over…
Abstract Number: 0226 • ACR Convergence 2020
Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis
Gerd Burmester¹, Vivian Bykerk², Maya Buch³, Yoshiya Tanaka⁴, Hideto Kameda⁵, Amy Praestgaard⁶, Hubert van Hoogstraten⁷, Antonio Fernandez-Nebro⁸ and Thomas Huizinga⁹, ¹Charité University Hospital Berlin, Berlin, Germany, ²Hospital for Special Surgery, New York, NY, ³Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Toho University, Tokyo, Japan, ⁶Sanofi, Cambridge, MA, ⁷Sanofi, Bridgewater, NJ, ⁸University of Malaga, Malaga, Spain, ⁹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs like methotrexate (MTX) has demonstrated improvement in symptomatic and functional outcomes in patients (pts)…
Abstract Number: 0316 • ACR Convergence 2020
High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis
Siba Raychaudhuri¹, Yasser Abdelhafez², Soumajyoti Sarkar³, Smriti Raychaudhuri⁴ and Abhijit Chaudhari², ¹Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, ²University of California, Davis, Sacramento, CA, ³University of California, Davis, Davis, ⁴VA Sacramento Medical Center, Davis, CA
Background/Purpose: To validate high-sensitivity PET/CT as a diagnostic test we have explored the association of total-body and extremity PET/CT measures with the standardized psoriatic arthritis…
Abstract Number: 0486 • ACR Convergence 2020
Differences in Low-density Lipoprotein (LDL) Particle Composition and Oxidation May Underlie the Paradoxical Association of Low LDL with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth¹, Elizabeth Hernandez¹ and Matthew Budoff¹, ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA
Background/Purpose: Rheumatoid arthritis (RA) patients in the lowest LDL group (< 70mg/dl) experience unexpectedly high cardiovascular risk. We first explored whether this group (Group 1)…
Abstract Number: 0589 • ACR Convergence 2020
The Ideal Mhealth Application for Rheumatoid Arthritis: Qualitative Findings from Stakeholder Focus Groups
Diederik De Cock¹, Maryline Vandeputte², Rani Van Melder², Michael Doumen², Delphine Bertrand¹, Veerle Stouten¹, Sofia Pazmino¹, Rene Westhovens³ and Patrick Verschueren⁴, ¹KU Leuven, Leuven, Belgium, ²KU Leuven, Leuven, ³University Hospitals Leuven, Belgium, Leuven, Belgium, ⁴University Hospital Leuven, Leuven, Belgium
Background/Purpose: Early access to specialized rheumatological care is under increasing pressure. Many countries are currently confronted with a relative shortage of practicing rheumatologists, while recent…
Abstract Number: 0751 • ACR Convergence 2020
Serum Interferon-Alpha Levels Could Help Identify a Subgroup of Rheumatoid Arthritis with Poorer Physical Function and Higher Physician Global Assessment
Yong Gil Hwang¹, Lei Zhu², Dongwen Wu² and Larry Moreland³, ¹University of Pittsburgh Physicians, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Colorado, Colorado
Background/Purpose: Our objective was to identify the clinical significance of serum interferon-alpha levels in patients with established rheumatoid arthritis (RA).Methods: Serum samples and clinical data…
Abstract Number: 0768 • ACR Convergence 2020
Dynamics of Follicular Helper T Cells Subsets in Rheumatoid Arthritis Patients Before and After Treatment
Paola Virginia Ferrero¹, Luisina Onofrio¹, Cristina del Valle Acosta¹, Estefania Raquel Zacca¹, Nicolas Eric Ponce², Eduardo Mussano¹, Ignacio Isaac Cadile¹, Laura Onetti¹, Marina Werner¹, Alicia Beatriz Costantino¹, Eva Virginia Acosta Rodriguez³ and Adriana Gruppi², ¹HOSPITAL NACIONAL DE CLINICAS, FACULTAD DE MEDICINA, UNIVERSIDAD NACIONAL DE CORDOBA, CORDOBA, Cordoba, Argentina, ²FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Cordoba, Argentina, ³FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Argentina
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by the production of autoantibodies like rheumatoid factor and anti- citrullinated protein. CD4+ follicular helper T…
Abstract Number: 0785 • ACR Convergence 2020
Identification of Recruited CCR2+ Inflammatory Monocytes in a Mouse Model of RA-associated Lung Disease with Potential Role for resolvin-D1 in Reducing Monocyte Inflammatory Responses
Austin Barry¹, Geoffrey Thiele¹, Ted Mikuls¹, Michael Duryee¹, Amy Nelson¹, Rohit Gaurav¹, Bryant England¹ and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for comorbid chronic lung disease, with premature mortality. Therapies for RA-associated lung disease are…
Abstract Number: 0802 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness
Yoshiya Tanaka¹, Hisashi Yamanaka², Leslie Harrold³, Tin-chi Lin³, Ekta Agarwal⁴, Jose L Rivas⁵, Naonobu Sugiyama⁶, Jeffrey Greenberg⁷ and Mitsumasa Kishimoto⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ³Corrona, LLC, Waltham, MA, ⁴Pfizer, Inc., Princeton Jct, NJ, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Japan Inc, Tokyo, Japan, ⁷Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁸Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: There are several conventional synthetic, targeted synthetic and biological disease-modifying anti-rheumatic medications (DMARDs) approved for the treatment of rheumatoid arthritis (RA) in Japan. Little…
Abstract Number: 0818 • ACR Convergence 2020
Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis
Miriam Retuerto¹, Elisa Trujillo², Cristina Valero³, Cruz Fernández-Espartero⁴, Christian Soleto-Kharkovskaya⁵, Andrea García Valle⁶, Elena Aurrecoechea⁷, Marta Garijo⁸, Javier Loricera⁹ and Jose Luis Pablos¹⁰, ¹Hospital universitario 12 de octubre, Madrid, Spain, ²Hospital universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ⁴H. Mostoles, Madrid, Spain, ⁵Gregorio Marañón University Hospital, Madrid, ⁶H. Palencia, Palencia, Spain, ⁷Hospital de Sierrallana, Torrelavega, Spain, ⁸Hospital de Sagunto, Valencia, Spain, ⁹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Different jakinibs have shown efficacy in rheumatoid arthritis (RA) but in an important proportion of patients, insufficient response leads to therapy withdrawal. The different…
Abstract Number: 0939 • ACR Convergence 2020
Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial
Jeffrey R Curtis¹, Paul Emery², Elaine Karis³, Boulos Haraoui⁴, Vivian Bykerk⁵, Priscilla Yen³, Gregory Kricorian⁶ and James Chung³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ³Amgen, Inc., Thousand Oaks, CA, ⁴Rheumatology Institute of Montréal, Montreal, Canada, ⁵Hospital for Special Surgery, New York, NY, ⁶Amgen Inc., Thousand Oaks, CA
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) in remission on combination therapy (Combo) of methotrexate (MTX)+etanercept (ETN) face ongoing medication burden and long-term safety/tolerability concerns related…
Abstract Number: 1000 • ACR Convergence 2020
Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women
Kazuki Yoshida¹, Jiaqi Wang², Susan Malspeis³, Bing Lu⁴, Lauren C. Prisco³, Lily Martin³, Julia Ford², Karen Costenbader⁵, Elizabeth Karlson² and Jeffrey Sparks⁶, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Personal cigarette smoking has been strongly associated with the risk for developing seropositive RA. Previous studies concerning passive smoking conflict; some suggested that childhood…
Abstract Number: 1016 • ACR Convergence 2020
Annual Cardiac or Orthopedic Procedure Volume in Gout versus Rheumatoid Arthritis: A National Time-trends Study
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The hospitalization rate for gout has been increasing in recent years with a reduction in people with RA. To our knowledge, there are no…
Abstract Number: 1187 • ACR Convergence 2020
Red Cell Distribution Width Is Associated with ASCVD Risk Score and CVD in RA After Initiation of Methotrexate
Ibtissam Gad¹, Sofi Damjanovska², Lenche Kostadinova³, Alyssa Lange⁴, Christopher Burant⁴, Brigid Wilson⁵, Taissa Bej⁵, Nora Singer⁶, Maya Mattar⁷, David Zidar⁸ and Donald Anthony⁹, ¹Case Western Reserve/ Cleveland VA Medical Center, Cleveland Heights, OH, ²Case Western Reserve University/Cleveland VA Medical Center, Cleveland Heights, OH, ³(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, ⁴Case Western Reserve University, Cleveland, ⁵Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ⁶The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ⁷Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ⁸Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁹Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Rheumatoid arthritis (RA) has been shown to be associated with increased risk of cardiovascular disease (CVD) and mortality. Red cell distribution width (RDW) represents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].